Selective Serotonin Reuptake Inhibitors

Preskorn, Sheldon; Ross, Ruth; Stanga, C. Y.

doi:10.1007/978-3-642-18500-7_9

Cited by 47 publications

(36 citation statements)

References 56 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This 5-HT/DA interaction plays a critical role in the action of antidepressant drugs. 5-HTselective reuptake inhibitors (SSRIs) for example, block 5-HT transporter (5-HTT) function to increase 5-HT signaling, but may also induce side effects typically associated with reduced DA signaling, such as anhedonia, apathy, reduced libido, akathisia, and extrapyramidal motor symptoms (EPSs) (Settle, 1998;Cassano and Fava, 2004;Damsa et al, 2004;Preskorn et al, 2004). These side effects can lead to discontinuation even when treatment is efficacious (Kaplan, 1997;Chelben et al, 2001) and reduce response rates (Rush et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Chronic 5-HT Transporter Blockade Reduces DA Signaling to Elicit Basal Ganglia Dysfunction

Morelli

Moore²,

Rebello³

et al. 2011

J. Neurosci.

View full text Add to dashboard Cite

Serotonin (5-HT)-selective reuptake inhibitors (SSRIs) are widely administered for the treatment of depression, anxiety, and other neuropsychiatric disorders, but response rates are low, and side effects often lead to discontinuation. Side effect profiles suggest that SSRIs inhibit dopaminergic activity, but mechanistic insight remains scarce. Here we show that in mice, chronic 5-HT transporter (5-HTT) blockade during adulthood but not during development impairs basal ganglia-dependent behaviors in a dose-dependent and reversible fashion. Furthermore, chronic 5-HTT blockade reduces striatal dopamine (DA) content and metabolism. A causal relationship between reduced DA signaling and impaired basal ganglia-dependent behavior is indicated by the reversal of behavioral deficits through L-DOPA administration. Our data suggest that augmentation of DA signaling would reduce side effects and increase efficacies of SSRIbased therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Chronic 5-HT Transporter Blockade Reduces DA Signaling to Elicit Basal Ganglia Dysfunction

Morelli

Moore²,

Rebello³

et al. 2011

J. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Among the various neurotransmitters, the serotonergic (5-HT) system is often the targets of drugs (e.g., antidepressants such as selective serotonin reuptake inhibitors (SSRIs)) prescribed for the treatment of neuropsychiatric illnesses [5]- [7]. Biologically based computational models of the serotonergic system are increasingly becoming available [8]- [16].…”

mentioning

confidence: 99%

Reduced Computational Models of Serotonin Synthesis, Release, and Reuptake

Flower

Wong‐Lin

2014

IEEE Trans. Biomed. Eng.

View full text Add to dashboard Cite

Multiscale computational models can provide systemic evaluation and prediction of neuropharmacological drug effects. To date, little computational modeling work has been done to bridge from intracellular to neuronal circuit level. A complex model that describes the intracellular dynamics of the presynaptic terminal of a serotonergic neuron has been previously proposed. By systematically perturbing the model's components, we identify the slow and fast dynamical components of the model, and the reduced slow or fast mode of the model is computationally significantly more efficient with accuracy not deviating much from the original model. The reduced fast-mode model is particularly suitable for incorporating into neurobiologically realistic spiking neuronal models, and hence for large-scale realistic computational simulations. We also develop user-friendly software based on the reduced models to allow scientists to rapidly test and predict neuropharmacological drug effects at a systems level.

show abstract

“…The effect of selective serotonin reuptake inhibitors (SSRIs) is a notable exception to this pattern of shared treatment response: SSRIs are the most widely prescribed class of antidepressant medication used to treat depressive and anxiety disorders in many countries, such as the United States (e.g., Preskorn, Ross, & Stanga, 2004), but are associated with a high risk for antidepressant-induced sexual dysfunction (Keks, Hope & Culhane, 2014; Balon, 2006b). The precise mechanisms underlying this relationship are not known.…”

Section: Part 2: Evidence That Supports the Formation Of The Hypothesmentioning

confidence: 99%

A Place for Sexual Dysfunctions in an Empirical Taxonomy of Psychopathology

Forbes

Baillie

Eaton

et al. 2017

The Journal of Sex Research

View full text Add to dashboard Cite

Sexual dysfunctions commonly co-occur with various depressive and anxiety disorders. An emerging framework for understanding the classification of mental disorders suggests that such comorbidity is a manifestation of underlying dimensions of psychopathology (or “spectra”). In this review, we synthesize the evidence that sexual dysfunctions should be included in the empirical taxonomy of psychopathology as part of the internalizing spectrum, which accounts for comorbidity among the depressive and anxiety disorders. The review has four parts. Part 1 summarizes the empirical basis and utility of the empirical taxonomy of psychopathology. Part 2 reviews the prima facie evidence for the hypothesis that sexual dysfunctions are part of the internalizing spectrum (i.e., high rates of comorbidity; shared cognitive, affective, and temperament characteristics; common neural substrates and biomarkers; shared course and treatment response; and the lack of causal relationships between them). Part 3 critically analyzes and integrates the results of the eight studies that have addressed this hypothesis. Finally, Part 4 examines the implications of reconceptualizing sexual dysfunctions as part of the internalizing spectrum, and explores avenues for future research.

show abstract

Selective Serotonin Reuptake Inhibitors

Cited by 47 publications

References 56 publications

Chronic 5-HT Transporter Blockade Reduces DA Signaling to Elicit Basal Ganglia Dysfunction

Chronic 5-HT Transporter Blockade Reduces DA Signaling to Elicit Basal Ganglia Dysfunction

Reduced Computational Models of Serotonin Synthesis, Release, and Reuptake

A Place for Sexual Dysfunctions in an Empirical Taxonomy of Psychopathology

Contact Info

Product

Resources

About